Yu Liping, Yan Junjuan, Wen Fang, Wang Fang, Liu Jingran, Cui Yonghua, Li Ying
Department of Psychiatry, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
J Child Adolesc Psychopharmacol. 2020 Jun;30(5):316-325. doi: 10.1089/cap.2019.0161. Epub 2020 Mar 19.
Tic disorders (TDs) are chronic neuropsychiatric disorders that usually begin in childhood. Currently, antipsychotic drugs, such as aripiprazole and risperidone, are frequently used to treat TD. However, adverse reactions limit their further usage. The efficacy of topiramate has been reported in recent studies. This study aimed to investigate the efficacy and tolerability of topiramate in the treatment of children with TDs. In this study, we performed a meta-analysis to assess the efficacy and tolerability of topiramate for TDs and identified the randomized controlled trials to evaluate topiramate for children with TDs from PubMed, the China National Knowledge Infrastructure database, Web of Science, and relevant reference lists. Quality assessment followed the Cochrane Handbook for Systematic Reviews of Interventions. A modified Jadad scale was used to assess the quality of included studies. Risk ratio (RR) was calculated as the effect size of efficacy and tolerability of topiramate for TDs. A total of 15 studies involving 1070 participants aged 2-17 were included in the present meta-analysis, and 693 (64.71%) participants were male cases, with 14 studies evaluating the efficacy of topiramate for the treatment of TD. The results suggested that topiramate was more effective than control drugs (RR: 1.13, 95% confidence interval: [1.06-1.20], = 36%, = 20.31, = 0.09). For the adverse events, there were 15 trials included in the meta-analysis, and the results showed that topiramate had fewer adverse events than control drugs (RR: 0.54, 95% confidence interval: [0.46-0.65], = 45%, = 25.49, = 0.03). Compared with haloperidol and tiapride, topiramate appears to be a promising medication with good efficacy and tolerability for children with TDs. In future studies, large-sample, double-blind, placebo-controlled trials are needed to confirm its efficacy and tolerability compared with atypical antipsychotic agents (such as risperidone or aripiprazole).
抽动障碍(TDs)是通常始于儿童期的慢性神经精神障碍。目前,抗精神病药物,如阿立哌唑和利培酮,常用于治疗抽动障碍。然而,不良反应限制了它们的进一步使用。近期研究报道了托吡酯的疗效。本研究旨在调查托吡酯治疗抽动障碍患儿的疗效和耐受性。在本研究中,我们进行了一项荟萃分析以评估托吡酯治疗抽动障碍的疗效和耐受性,并从PubMed、中国知网数据库、科学引文索引数据库及相关参考文献列表中确定了评估托吡酯治疗抽动障碍患儿的随机对照试验。质量评估遵循Cochrane干预系统评价手册。采用改良的Jadad量表评估纳入研究的质量。计算风险比(RR)作为托吡酯治疗抽动障碍疗效和耐受性的效应量。本荟萃分析共纳入15项研究,涉及1070名2至17岁的参与者,其中693例(64.71%)为男性病例,有14项研究评估了托吡酯治疗抽动障碍的疗效。结果表明,托吡酯比对照药物更有效(RR:1.13,95%置信区间:[1.06 - 1.20],χ² = 36%,I² = 20.31,P = 0.09)。对于不良事件,荟萃分析纳入了15项试验,结果显示托吡酯的不良事件比对照药物少(RR:0.54,95%置信区间:[0.46 - 0.65],χ² = 45%,I² = 25.49,P = 0.03)。与氟哌啶醇和硫必利相比,托吡酯似乎是一种对抽动障碍患儿疗效良好且耐受性好的有前景的药物。在未来的研究中,需要进行大样本、双盲、安慰剂对照试验,以确认其与非典型抗精神病药物(如利培酮或阿立哌唑)相比的疗效和耐受性。